Figure 2
From: Neuroprotective effects of naltrexone in a mouse model of post-traumatic seizures
Phospho-MAPK levels and nitro-oxidative stress markers in the CTX. Western blot analysis of phospho-p38 (MAP kinase), 3-NT (a marker of protein nitrosylation), and iNOS from the CTX at 8 days and 3 months post-TBI (a). Increased levels of phospho-p38, 3-NT and iNOS were detected in the CTX at both time points compared to sham (b–d). NTX mitigated all biomarker levels when compared to the TBI group (except 3-NT at 3 months). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; One-way ANOVA with Tukey’s post hoc test; n = 6–8. All the data is represented as standard error mean (SEM). S sham, TBI traumatic brain injury, T + N TBI with naltrexone, NTX naltrexone only, without TBI.
